Free tool
FAERS Monitor: Zynyz
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming BLA 761334 or its brand name (Zynyz, Retifanlimab-Dlwr). Reports on generic versions are filed under their own applications.
Reports
72
Serious
43
60% of reports
Hospitalization
10
Death reported
9
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- off label use25
- disease progression11
- anal squamous cell carcinoma6
- anal cancer5
- death4
- malignant neoplasm progression4
- nausea4
- anaemia3
- condition aggravated3
- decreased appetite3
- malaise3
- neuropathy peripheral3
- product dose omission issue3
- thrombocytopenia3
- general physical health deterioration2
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2023 | 1 |
| 2024 | 3 |
| 2025 | 24 |
| 2026 | 44 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,087 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| anal squamous cell carcinomaSignal | 6 | 5809.6 | 2678.2 | 28,709 |
| anal cancerSignal | 5 | 1515.1 | 648.9 | 6,096 |
| disease progressionSignal | 11 | 27.2 | 15.8 | 253 |
| malignant neoplasm progressionSignal | 4 | 11.4 | 4.4 | 28 |
| neuropathy peripheralSignal | 3 | 9.2 | 3.0 | 15 |
| off label useSignal | 25 | 8.3 | 6.1 | 161 |
| thrombocytopeniaSignal | 3 | 7.8 | 2.6 | 12 |
| general physical health deterioration | 2 | 5.0 | 1.3 | 3 |
| anaemiaSignal | 3 | 4.6 | 1.5 | 5 |
| decreased appetite | 3 | 3.8 | 1.2 | 4 |
| product dose omission issue | 3 | 3.0 | 1.0 | 2 |
| condition aggravated | 3 | 2.9 | 1.0 | 2 |
| malaise | 3 | 2.0 | 0.7 | 1 |
| nausea | 4 | 1.5 | 0.6 | 0 |
| death | 4 | 1.4 | 0.5 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.